Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2007

01-04-2007 | Current Opinion

When Should Clozapine Be Initiated in Schizophrenia?

Some Arguments For and Against Earlier Use of Clozapine

Author: Robert Kerwin

Published in: CNS Drugs | Issue 4/2007

Login to get access

Abstract

Clozapine is one of the original atypical antipsychotics. It was withdrawn from the market in 1974 because of haematological safety concerns, but since 1989 has enjoyed a renaissance for the management of treatment-resistant schizophrenia under systems where case registration allows regular haematological monitoring. Clozapine continues to show enduring superiority across many aspects of the clinical pharmacology of the treatment of schizophrenia, e.g. it has specific antisuicidal properties and recent broader trials have shown continuing superiority in wide groups of patients.
This article considers some of the arguments for unshackling clozapine from its current license for schizophrenia (its superiority overall in treatment-resistant schizophrenia, its potential for use in first-episode patients, and its anti-suicidal potential), and tries to synthesise these into some of the national guidelines available for the treatment of schizophrenia.
Literature
1.
Baldessarini RJ, Frankenburg FR. Clozapine: a novel agent. N Engl J Med 1991; 324(11): 745–54
2.
3.
Idanpaan HJ, Alhave E, Olkinnonora M, et al. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11: 94–8
4.
Fitton A, Heel RC. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990; 40: 722–47PubMedCrossRef
5.
Claghorn J, Honigfield G, Abuzzahab FS. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7: 377–84PubMedCrossRef
6.
Newcomer HJ, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychol 2006; 51: 480–91
7.
Anderman B, Griffith RW. Clozapine induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 1977; 11: 199–201PubMedCrossRef
8.
Altamura AC, Bassetti R, Cattaneo E, et al. Some biological correlates of drug resistance in schizophrenia: a multidimensional approach. World J Biol Psychiatry 2005; 6Suppl. 2: 23–30PubMedCrossRef
9.
Cole JD, Goldberg SC, Davis JM. Drugs in the treatment of psychosis: controlled studies. In: Solomon P, editor. Psychiatric drugs. New York: Groller and Stratton, 1966: 153–60
10.
Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacol Bull 1993; 29: 309–14PubMed
11.
Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96PubMedCrossRef
12.
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812CrossRef
13.
Meltzer HY, Bastani B, Young-Kwon H, et al. A prospective study of clozapine in treatment resistant patients: a preliminary report. Psychopharmacology (Berl) 1989; 99Suppl. 68: S68–72CrossRef
14.
Brier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151(1): 20–6
15.
Kane J, Marder SR, Schooler NR, et al. Efficacy of clozapine versus haloperidol in a long term clinical trial [abstract]. American Psychiatric Association Annual Meeting; 995 May 20–25; Miami (FL)
16.
Lieberman JA, Stroup T, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23PubMedCrossRef
17.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163: 611–22PubMedCrossRef
18.
McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 606–10CrossRef
19.
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second versus first generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study (CUtLASS). Arch Gen Psychiatry 2006; 63: 1079–87PubMedCrossRef
20.
Lewis SW, Barnes TW, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bull 2006; 32: 715–36CrossRef
21.
Munro J, O’Sullivan D, Arana A, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576–80PubMedCrossRef
22.
Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1998; 8: 671–7
23.
Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483–8PubMedCrossRef
24.
Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59Suppl. 3: 3–7PubMed
25.
Bastani B, Alphs LD, Meltzer HG. Development of the Clozaril patient management system. Psychopharmacology (Berl) 1989; 99 Suppl.: S122–5CrossRef
26.
Johnstone EC, Crow TJ, Johnson AL, et al. The Northwick Park study of first episodes of schizophrenia: I. Presentation of the illness and problems relating to admission. Br J Psychiatry 1986; 148: 115–20
27.
Crow TJ, MacMillan JF, Johnson AL, et al. Northwick Park study of first episodes of schizophrenia: II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120–7
28.
Lieberman JA, Jody D, Geisler SH, et al. Time course and biological correlates of treatment response to first episode schizophrenia. Arch Gen Psychiatry 1993; 50: 369–76PubMedCrossRef
29.
Larsen TK, Johannessen JO, Opjordsmoen S. First episode schizophrenia with long duration of psychosis: pathways to care. Brit Journal Psychiatry 1998; 172Suppl. 33: 45–52
30.
Barnes TRE, Hutton SB, Chapman MJ, et al. West London first episode study of schizophrenia: clinical correlates of duration of untreated psychosis. Br J Psychiatry 2000; 177: 207–11PubMedCrossRef
31.
Loebel AD, Lieberman JA, Alum JM, et al. Duration of psychosis and outcome in first episode schizophrenia. Am J Psychiatry 1992; 149: 1183–8PubMed
32.
Perkins DO, Gu K, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in first episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785–804PubMedCrossRef
33.
Norman RMG, Lewis SW, Marshall M. Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry 2005; 187: S19–23CrossRef
34.
Lieberman JA, Tollefson GD, Zipursky CC, et al. Antipsychotic drug effects on brain morphology in first episode psychosis. Arch Gen Psychiatry 2005; 62: 361–76PubMedCrossRef
35.
Verdoux H, Bergey C, Assens F, et al. Prediction of duration of psychosis before first admission. Eur Psychiatry 1998; 13: 346–52PubMedCrossRef
36.
Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment naïve first episode schizophrenia: a 52 week randomised trial of clozapine versus chlorpromazine. Neuropsychopharmacology 2003; 28: 995–1003PubMed
37.
Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30–4PubMedCrossRef
38.
Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 1990; 147: 602–7PubMed
39.
Nyman A, Jonsson H. Patterns of self destructive behaviour in schizophrenia. Acta Psychiatrica Scandinavica 1986; 73: 252–62PubMedCrossRef
40.
Arelsson R, Lagerkuist-Briggs M. Factors predicting suicide in psychotic patients. Eur Arch Psychiatry Clin Neurosci 1992; 241: 259–66CrossRef
41.
Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk benefit assessment. Am J Psychiatry 1995; 152: 183–90PubMed
42.
Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). N Engl J Med 2003; 60: 82–91
43.
Alphs L, Anand R, Islam MZ, et al. The International Suicide Prevention Trial (InterSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behaviour in schizophrenia and schizophrenic patients. Schizophrenia Bull 2004; 30: 577–86CrossRef
44.
Duggan A, Warner J, Knapp M, et al. Modelling the impact of clozapine on suicide in patients with treatment resistant schizophrenia in the UK. Br J Psychiatry 2003; 182: 505–8PubMedCrossRef
45.
Modestin J, Dal Pian D, Argawalla P. Clozapine diminishes suicidal behaviour: a retrospective evaluation of clinical records. J Clin Psychiatry 2005; 66: 534–8PubMedCrossRef
46.
Sernyak MJ, Hoff R, Rosenheck MD. Clozapine and suicide [letter]. Psychiatric Serv 1999; 50: 116
47.
Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta analysis. Schizophr Res 2005; 73: 139–45PubMedCrossRef
48.
Khan A, Khan SR, Leventhal RM, et al. Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001; 158: 1449–54PubMedCrossRef
49.
Davis JM, Chen N, Glick ID. A meta analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–64PubMedCrossRef
50.
Tiihonan J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333(7561): 224. Epub 2006 Jul 6CrossRef
51.
Angst J, Bente D, Berner P. Das klinische wilkungbild von clozapine. Pharmako-Psychiatrie 1971; 4: 200–11
52.
Green AI, Schildkraut JJ. Should clozapine be a first line treatment for schizophrenia? The rationale for a double blind clinical trial in first episode patients. Harv Rev Psychiatry 1995; 3: 1–9PubMedCrossRef
53.
54.
Woerner G, Robertson DG, Alvil MA, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003; 160: 1514–6PubMedCrossRef
55.
Lieberman JA, Alvil JM, Woerner G, et al. Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital. Schizophr Bull 1992; 18: 351–71PubMedCrossRef
56.
Kelly DL, Conley RR, Carpenter WT. First episode schizophrenia: a focus on pharmacological treatment and safety considerations. Drugs 2005; 65: 1113–38PubMedCrossRef
57.
Hofer A, Hummer M, Kemmier G, et al. The safety of clozapine in the treatment of first and multiple episode patients with treatment resistant schizophrenia. Int J Neuropsychopharmacology 2003; 6: 201–6CrossRef
58.
Wang PS, Ganz DA, Benner JS, et al. Should clozapine continue to be restricted to third line status for schizophrenia: a decision analytic model. J Ment Health Policy Econ 2004; 7: 77–85PubMed
59.
National Institute for Healthcare and Clinical Excellence (NICE): Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal no. 43, 2002 [online]. Available from URL: http://​www.​nice.​org.​uk [Accessed 2006 Dec 18]
60.
Royal Australian and New Zealand College of Psychiatrists. Clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry 2005; 39: 1–30CrossRef
61.
American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd draft. Washington, DC: American Psychiatric Association, 2003
Metadata
Title
When Should Clozapine Be Initiated in Schizophrenia?
Some Arguments For and Against Earlier Use of Clozapine
Author
Robert Kerwin
Publication date
01-04-2007
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2007
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721040-00002

Other articles of this Issue 4/2007

CNS Drugs 4/2007 Go to the issue

Adis Drug Evaluation

Sodium Oxybate

Review Article

Fungal Infections of the CNS

In Memory

Professor Robert W. Kerwin, MA, PhD, MB BChir, DSc, FRCPsych 1955–2007

Correspondence

Naturalistic Treatment of Alzheimer’s Disease with Galantamine

Therapy In Practice

Depression and Anxiety in Individuals with Amyotrophic Lateral Sclerosis

Original Research Article

Cost Effectiveness of Long-Term Treatment with Eszopiclone for Primary Insomnia in Adults